Condition: Recurrent Glioma · Solid Tumor · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.
This description comes directly from the study's public registry record.
Sa Xiao, PHD · +86-15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Affiliated Cancer Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| ZhuJiang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| Shenzhen Second People's Hospital | Shenzhen, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Xi'an Jiao Tong University | Xian, Shanxi, China | Recruiting |
| West China Hospital，Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04794972